[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IS2492B - Erythropoietin afleiður - Google Patents

Erythropoietin afleiður

Info

Publication number
IS2492B
IS2492B IS5554A IS5554A IS2492B IS 2492 B IS2492 B IS 2492B IS 5554 A IS5554 A IS 5554A IS 5554 A IS5554 A IS 5554A IS 2492 B IS2492 B IS 2492B
Authority
IS
Iceland
Prior art keywords
erythropoietin derivatives
erythropoietin
derivatives
Prior art date
Application number
IS5554A
Other languages
English (en)
Other versions
IS5554A (is
Inventor
Sebastian Bailon Pascal
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495518&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2492(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of IS5554A publication Critical patent/IS5554A/is
Publication of IS2492B publication Critical patent/IS2492B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IS5554A 1999-07-02 2000-06-30 Erythropoietin afleiður IS2492B (is)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14225499P 1999-07-02 1999-07-02
US15022599P 1999-08-23 1999-08-23
US15154899P 1999-08-31 1999-08-31
US16615199P 1999-11-17 1999-11-17

Publications (2)

Publication Number Publication Date
IS5554A IS5554A (is) 2001-01-02
IS2492B true IS2492B (is) 2009-02-15

Family

ID=27495518

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5554A IS2492B (is) 1999-07-02 2000-06-30 Erythropoietin afleiður

Country Status (52)

Country Link
US (2) US6583272B1 (is)
EP (2) EP1839676A3 (is)
JP (2) JP3727009B2 (is)
KR (1) KR100593143B1 (is)
CN (2) CN1283664C (is)
AR (2) AR024625A1 (is)
AT (1) ATE370748T1 (is)
AU (1) AU736067B2 (is)
BG (1) BG65449B1 (is)
BR (2) BR0002276A (is)
CA (1) CA2310536C (is)
CO (1) CO5190661A1 (is)
CY (2) CY1107719T1 (is)
CZ (1) CZ299516B6 (is)
DE (3) DE122007000064I2 (is)
DK (1) DK1064951T3 (is)
DO (1) DOP2000000030A (is)
EA (1) EA003777B1 (is)
ES (2) ES2289985T3 (is)
FR (2) FR2795734B1 (is)
GB (2) GB2353281B (is)
GC (1) GC0000197A (is)
GE (1) GEP20022804B (is)
GT (1) GT200000109A (is)
HK (2) HK1068354A1 (is)
HR (1) HRP20000436B1 (is)
HU (1) HU226233B1 (is)
ID (1) ID26447A (is)
IL (1) IL137056A0 (is)
IS (1) IS2492B (is)
IT (1) IT1318606B1 (is)
LU (1) LU91363I2 (is)
MA (1) MA26746A1 (is)
MX (1) MXPA00006547A (is)
MY (1) MY128500A (is)
NL (1) NL300289I9 (is)
NO (2) NO327043B1 (is)
NZ (1) NZ505454A (is)
OA (1) OA11442A (is)
PA (1) PA8497801A1 (is)
PE (1) PE20010297A1 (is)
PL (1) PL202758B1 (is)
PT (1) PT1064951E (is)
RS (1) RS49928B (is)
SG (1) SG92717A1 (is)
SI (1) SI1064951T1 (is)
SK (1) SK286301B6 (is)
SV (1) SV2002000120A (is)
TN (1) TNSN00147A1 (is)
TR (1) TR200001956A2 (is)
TW (1) TWI235667B (is)
UY (1) UY26228A1 (is)

Families Citing this family (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2312188C (en) 1997-12-08 2010-06-29 Lexigen Pharmaceuticals Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
WO1999052562A2 (en) * 1998-04-15 1999-10-21 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
US7304150B1 (en) * 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
KR100827757B1 (ko) * 1999-08-09 2008-05-07 메르크 파텐트 게엠베하 복수의 시토킨-항체 복합체
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
CN1406249B (zh) * 2000-02-11 2010-06-16 默克专利股份有限公司 增加基于抗体的融合蛋白的循环半衰期
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
DE60109625T3 (de) † 2000-05-15 2017-08-03 F. Hoffmann-La Roche Ag Flüssige arzneizubereitung enthaltend ein erythropoietin derivat
KR20030064275A (ko) * 2000-06-29 2003-07-31 메르크 파텐트 게엠베하 면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
ES2320101T3 (es) * 2000-10-16 2009-05-19 Chugai Seiyaku Kabushiki Kaisha Eritropoyetina conjugada con mono-peg.
AU2002233230B2 (en) * 2000-12-20 2007-02-01 F. Hoffmann-La Roche Ag Erythropoietin conjugates
ATE505204T1 (de) * 2000-12-20 2011-04-15 Hoffmann La Roche Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
KR20090010127A (ko) * 2001-03-07 2009-01-28 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
ATE502053T1 (de) * 2001-05-03 2011-04-15 Merck Patent Gmbh Rekombinanter, tumorspezifischer antikörper und dessen verwendung
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
KR100467751B1 (ko) 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
EP2354791A1 (en) * 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
EP3520784A1 (en) * 2001-12-06 2019-08-07 Fibrogen, Inc. Hif prolyl hydroxylase inhibitor for treatment of anemia
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
US7129267B2 (en) 2002-03-11 2006-10-31 Janssen Pharmaceutica N.V. Methods for SHP1 mediated neuroprotection
EA010200B1 (ru) * 2002-07-01 2008-06-30 Дзе Кеннет С. Уоррен Инститьют, Инк. Рекомбинантные тканезащитные цитокины и кодирующие их нуклеиновые кислоты для защиты, восстановления и усиления чувствительных клеток, тканей и органов
CA2492775C (en) 2002-07-24 2011-06-21 F. Hoffmann-La Roche Ag Polyalkylene glycol acid additives
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US20050176627A1 (en) * 2002-09-09 2005-08-11 Anthony Cerami Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
BR0314227A (pt) 2002-09-11 2005-10-25 Fresenius Kabi De Gmbh Derivados de amido de hidroxialquila
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
JP4494977B2 (ja) * 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7587286B2 (en) 2003-03-31 2009-09-08 Xencor, Inc. Methods for rational pegylation of proteins
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
US7279174B2 (en) * 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
KR101160611B1 (ko) 2003-05-12 2012-06-28 아피맥스, 인크. 폴리(에틸렌 글리콜)로 변형된 펩티드 기재 화합물용 신규 스페이서 부분
KR20060028675A (ko) * 2003-05-12 2006-03-31 아피맥스, 인크. 신규한 폴리 (에틸렌 글리콜) 개질 화합물 및 그의 용도
US7084245B2 (en) 2003-05-12 2006-08-01 Affymax, Inc. Peptides that bind to the erythropoietin receptor
KR20120094001A (ko) * 2003-05-12 2012-08-23 아피맥스, 인크. 에리스로포이에틴 수용체에 결합하는 펩티드
CA2527665A1 (en) * 2003-05-30 2004-12-16 Centocor, Inc. Formation of novel erythropoietin conjugates using transglutaminase
US7662607B2 (en) * 2003-07-30 2010-02-16 New Century Pharmaceuticals, Inc. Chalaropsis lysozyme protein and its method of use in anti-bacterial applications
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
JP2007517769A (ja) * 2003-09-29 2007-07-05 ウォーレン ファーマシューティカルズ，インコーポレーテッド 敗血症および癒着形成の治療および予防のための組織保護性サイトカイン
CA2542353A1 (en) 2003-10-10 2005-04-21 Xencor, Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
PL1696947T3 (pl) * 2003-12-19 2014-08-29 Hoffmann La Roche Zastosowanie erytropoetyny w leczeniu zaburzeń dystrybucji żelaza w przewlekłych chorobach zapalnych jelit
EP1548031A1 (en) * 2003-12-22 2005-06-29 Dubai Genetics FZ-LLC Nature-identical erythropoietin
RU2370276C2 (ru) * 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
WO2005070973A2 (en) * 2004-01-21 2005-08-04 Nektar Therapeutics Al, Corporation Method of preparing propionic acid-terminated polymers
CN101001866A (zh) * 2004-02-02 2007-07-18 Ambrx公司 经修饰的人类干扰素多肽和其用途
EP1725589A1 (en) 2004-03-11 2006-11-29 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
US7253650B2 (en) 2004-05-25 2007-08-07 International Business Machines Corporation Increase productivity at wafer test using probe retest data analysis
WO2006060148A2 (en) * 2004-11-11 2006-06-08 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
BRPI0606934A2 (pt) 2005-01-25 2017-07-11 Cell Therapeutics Inc Conjugado de proteína biologicamente ativa, composição, molécula de dna quimérica, vetor, célula, e, métodos para preparar conjugado de proteína biologicamente ativa, e para determinar se um dado conjugado de proteína exibe uma meia-vida de plasma modificada comparada com a meia-vida intrínseca do polipeptídeo biologicamente ativo não conjungado
WO2006089228A2 (en) * 2005-02-16 2006-08-24 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
CA2625208A1 (en) * 2005-10-04 2007-04-12 Zymogenetics, Inc. Production and purification of il-29
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
JP2009514814A (ja) * 2005-10-21 2009-04-09 シナジェバ・バイオファーマ・コーポレイション グリコール化およびグリコシル化された家禽類由来の治療用たんぱく質
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
WO2007100902A2 (en) * 2006-02-28 2007-09-07 Oligasis Corporation Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
EP1997505A4 (en) 2006-03-22 2013-02-13 Chugai Pharmaceutical Co Ltd PREPARATION OF ERYTHROPOIETIN SOLUTION
PT2054074E (pt) * 2006-08-04 2014-11-07 Prolong Pharmaceuticals Llc Eritropoietina modificada
US8497246B2 (en) 2006-08-18 2013-07-30 Armagen Technologies, Inc. Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
EP2120998B1 (en) 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Modified erythropoietin polypeptides and uses thereof for treatment
CA2676036A1 (en) * 2007-02-02 2008-08-14 Amgen Inc. Hepcidin, hepcidin antagonists and methods of use
WO2008137066A1 (en) * 2007-05-02 2008-11-13 The Board Of Regents Of The University Of Oklahoma Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
CL2008002053A1 (es) * 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
AR067536A1 (es) * 2007-07-17 2009-10-14 Hoffmann La Roche Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
US8974791B2 (en) 2007-07-27 2015-03-10 Armagen Technologies, Inc. Methods and compositions for increasing α-L-iduronidase activity in the CNS
ES2750254T3 (es) 2007-09-27 2020-03-25 Amgen Inc Formulaciones farmacéuticas
EP2219602A1 (en) 2007-11-15 2010-08-25 Amgen, Inc Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
US8101706B2 (en) 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
EP3042922B1 (en) 2008-01-11 2017-07-19 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
CA2711826C (en) 2008-01-25 2018-02-27 Amgen Inc. Ferroportin antibodies and methods of use
EP2247743B1 (en) 2008-02-08 2016-04-06 Ambrx, Inc. Modified leptin polypeptides and their uses
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
NZ601248A (en) 2008-04-14 2014-06-27 Halozyme Inc Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
EP2816059A1 (en) 2008-05-01 2014-12-24 Amgen, Inc Anti-hepcidin antibodies and methods of use
EP2926825A1 (en) 2008-06-27 2015-10-07 Duke University Therapeutic agents comprising elastin-like peptides
ES2631915T3 (es) 2008-09-26 2017-09-06 Ambrx, Inc. Polipéptidos modificados de eritropoyetina animal y sus usos
JP6018753B2 (ja) 2008-11-13 2016-11-02 ザ・ジェネラル・ホスピタル・コーポレイションＴｈｅ Ｇｅｎｅｒａｌ Ｈｏｓｐｉｔａｌ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｍｐ−６の調節によって鉄の恒常性を制御するための方法および組成物
PT3037529T (pt) 2008-12-09 2019-05-31 Halozyme Inc Polipéptidos ph20 estendidos solúveis e suas utilizações
CA2748889A1 (en) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
US9289699B2 (en) 2009-07-30 2016-03-22 Hoffmann-La Roche Inc. Moveable chromatography column separator
WO2011024025A1 (en) * 2009-08-28 2011-03-03 Avesthagen Limited An erythropoietin analogue and a method thereof
EP2477603B1 (en) 2009-09-17 2016-03-30 Baxalta Incorporated Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
KR20120117728A (ko) * 2009-09-23 2012-10-24 바이오제너릭스 에이지 재조합 인간 에리트로포이에틴(ｅｐｏ)의 정제 방법, 이렇게 정제된 ｅｐｏ 및 이를 포함하는 약학적 조성물
US8834874B2 (en) 2009-10-09 2014-09-16 Armagen Technologies, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS
CA2778105C (en) 2009-10-23 2019-04-02 Amgen Inc. Vial adapter and system
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
SG183561A1 (en) * 2010-04-27 2012-09-27 Scil Technology Gmbh Stable aqueous mia/cd-rap formulations
SG194370A1 (en) 2010-06-07 2013-11-29 Amgen Inc Drug delivery device
KR20130125753A (ko) 2010-07-20 2013-11-19 할로자임, 아이엔씨 항-히알루로난제 투여와 관련된 유해 부작용의 치료
BR112013005890B1 (pt) 2010-09-14 2022-02-08 F Hoffmann-La Roche Ag Método para purificar eritropoietina peguilada
RU2584176C2 (ru) 2011-02-02 2016-05-20 Ф. Хоффманн-Ля Рош Аг Держатель для хроматографической колонки
EP2672958A1 (en) 2011-02-08 2013-12-18 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
US9480624B2 (en) 2011-03-31 2016-11-01 Amgen Inc. Vial adapter and system
CA3021845C (en) 2011-04-20 2022-03-29 Amgen Inc. Autoinjector apparatus
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
RS57589B1 (sr) 2011-10-14 2018-11-30 Amgen Inc Uređaji za ubrizgavanje i postupak za sklapanje
AU2012328880B2 (en) 2011-10-24 2017-02-23 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
ES2983576T3 (es) 2011-12-02 2024-10-23 Armagen Inc Métodos y composiciones para aumentar la actividad arilsulfatasa en el SNC
AU2012362141B2 (en) 2011-12-30 2017-09-21 Halozyme, Inc. PH20 polypeptide variants, formulations and uses thereof
LT2833905T (lt) 2012-04-04 2018-07-10 Halozyme, Inc. Derinių terapija su hialuronidaze ir į naviką nukreiptu taksanu
CN102816227A (zh) * 2012-08-30 2012-12-12 深圳赛保尔生物药业有限公司 回收促红细胞生成素的方法
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
SI3081249T1 (sl) 2012-11-21 2021-03-31 Amgen Inc. Naprava za dajanje zdravila
JP6643977B2 (ja) 2013-03-15 2020-02-12 アムゲン・インコーポレーテッド 体輪郭に適応可能な自動注入機デバイス
US10092703B2 (en) 2013-03-15 2018-10-09 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
TWI614041B (zh) 2013-03-15 2018-02-11 安美基公司 用於注射器之匣盒
KR102218494B1 (ko) 2013-03-15 2021-02-19 인트린식 라이프사이언시스, 엘엘씨 항-헵시딘 항체 및 그의 용도
BR112015024282B1 (pt) 2013-03-22 2022-05-17 Amgen Inc Injetor e método de montagem do injetor
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
US10702608B2 (en) 2013-09-08 2020-07-07 Kodiak Sciences Inc. Factor VIII zwitterionic polymer conjugates
CA3168888A1 (en) 2013-10-24 2015-04-30 Amgen Inc. Drug delivery system with temperature-sensitive control
US11097055B2 (en) 2013-10-24 2021-08-24 Amgen Inc. Injector and method of assembly
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
MX2016014561A (es) 2014-05-07 2017-06-21 Amgen Inc Autoinyetor con elementos reductores del shock.
EP3151883A1 (en) 2014-06-03 2017-04-12 Amgen Inc. Devices and methods for assisting a user of a drug delivery device
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
ES2727137T3 (es) 2014-08-28 2019-10-14 Halozyme Inc Terapia combinada con una enzima de degradación de hialuronano y un inhibidor de puntos de control inmunitario
WO2016049036A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
CA2964317C (en) 2014-10-14 2021-10-05 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
US10695506B2 (en) 2014-10-14 2020-06-30 Amgen Inc. Drug injection device with visual and audio indicators
CN107208076A (zh) 2014-10-17 2017-09-26 科达制药 丁酰胆碱酯酶两性离子聚合物缀合物
ES2785311T3 (es) 2014-12-19 2020-10-06 Amgen Inc Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario
JP6716566B2 (ja) 2014-12-19 2020-07-01 アムジエン・インコーポレーテツド 近接センサ付き薬物送達装置
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
US10583245B2 (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
WO2016138434A1 (en) 2015-02-27 2016-09-01 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
ES2755717T3 (es) 2015-12-09 2020-04-23 Amgen Inc Autoinyector con tapa de señalización
US11066465B2 (en) 2015-12-30 2021-07-20 Kodiak Sciences Inc. Antibodies and conjugates thereof
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
WO2017160799A1 (en) 2016-03-15 2017-09-21 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
CN105820232B (zh) * 2016-04-08 2019-05-17 昂德生物药业有限公司 单修饰聚乙二醇重组人促红素的制备方法及其制品和应用
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
MX2018013616A (es) 2016-05-13 2019-02-21 Amgen Inc Montaje de cubierta protectora de vial.
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
EP3478342A1 (en) 2016-07-01 2019-05-08 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
JP7177035B2 (ja) 2016-07-15 2022-11-22 エフ．ホフマン－ラ ロシュ アーゲー Ｐｅｇ化エリスロポエチンを精製するための方法
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
EP3532127A1 (en) 2016-10-25 2019-09-04 Amgen Inc. On-body injector
WO2018136398A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
EP3582825A1 (en) 2017-02-17 2019-12-25 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
US11369736B2 (en) 2017-02-17 2022-06-28 Amgen Inc. Cannula insertion and retraction mechanisms
CA3050927A1 (en) 2017-03-06 2018-09-13 Brian Stonecipher Drug delivery device with activation prevention feature
AU2018230546B2 (en) 2017-03-07 2024-03-21 Amgen Inc. Needle insertion by overpressure
IL268386B2 (en) 2017-03-09 2023-11-01 Amgen Inc Insertion mechanism for a drug delivery device
WO2018172219A1 (en) 2017-03-20 2018-09-27 F. Hoffmann-La Roche Ag Method for in vitro glycoengineering of an erythropoiesis stimulating protein
CN114588404B (zh) 2017-03-28 2024-07-09 美国安进公司 柱塞杆和注射器组件系统以及方法
CN110709121B (zh) 2017-06-08 2022-06-24 安进公司 扭矩驱动式药物递送装置
US11590294B2 (en) 2017-06-08 2023-02-28 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
US11541183B2 (en) 2017-06-22 2023-01-03 Amgen Inc. Device activation impact/shock reduction
BR112019027583A2 (pt) 2017-06-22 2020-10-06 Catalyst Biosciences, Inc. polipeptídeos de serina protease 1 tipo membrana (mtsp-1) modificados e métodos de uso
MX2019015479A (es) 2017-06-23 2020-02-20 Amgen Inc Dispositivo electronico de administracion de farmacos con tapa accionada por un conjunto de conmutador.
WO2019014014A1 (en) 2017-07-14 2019-01-17 Amgen Inc. NEEDLE INSERTION-RETRACTING SYSTEM HAVING DOUBLE TORSION SPRING SYSTEM
MA49626A (fr) 2017-07-21 2020-05-27 Amgen Inc Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage
WO2019022951A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSEMBLY METHOD THEREOF
EP3658206A1 (en) 2017-07-25 2020-06-03 Amgen Inc. Drug delivery device with container access system and related method of assembly
WO2019032482A2 (en) 2017-08-09 2019-02-14 Amgen Inc. HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM
WO2019036181A1 (en) 2017-08-18 2019-02-21 Amgen Inc. BODY INJECTOR WITH STERILE ADHESIVE PATCH
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
MA50611A (fr) 2017-10-04 2020-08-12 Amgen Inc Adaptateur d'écoulement destiné à un dispositif d'administration de médicament
EP4257164A3 (en) 2017-10-06 2024-01-17 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
US11464903B2 (en) 2017-10-09 2022-10-11 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
EP3703778A1 (en) 2017-11-03 2020-09-09 Amgen Inc. System and approaches for sterilizing a drug delivery device
JP2021501616A (ja) 2017-11-06 2021-01-21 アムジエン・インコーポレーテツド 配置及び流量検出を備える薬物送達デバイス
MA50569A (fr) 2017-11-06 2020-09-16 Amgen Inc Ensembles de remplissage-finition et procédés associés
US11191904B2 (en) 2017-11-10 2021-12-07 Amgen Inc. Plungers for drug delivery devices
JP7370969B2 (ja) 2017-11-16 2023-10-30 アムジエン・インコーポレーテツド 薬物送達デバイスの扉ラッチ機構
MA50903A (fr) 2017-11-16 2021-05-12 Amgen Inc Auto-injecteur avec détection de décrochage et de point d'extrémité
EP3731871B1 (en) 2017-12-29 2023-10-04 F. Hoffmann-La Roche AG Process for providing pegylated protein composition
JP7410860B2 (ja) 2017-12-29 2024-01-10 エフ． ホフマン－ラ ロシュ アーゲー Ｐｅｇ化タンパク質組成物を提供するための方法
PL3731873T3 (pl) 2017-12-29 2022-04-25 F. Hoffmann-La Roche Ag Sposób dostarczania kompozycji pegylowanego białka
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
CA3103681A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
MA53375A (fr) 2018-07-24 2021-06-02 Amgen Inc Dispositifs d'administration pour l'administration de médicaments
US12109389B2 (en) 2018-07-31 2024-10-08 Amgen Inc. Fluid path assembly for a drug delivery device
DK3613486T3 (da) * 2018-08-24 2021-01-04 Uga Biopharma Gmbh Metode og anlæg til rengøring af epo og/eller et epo-derivat
MA53724A (fr) 2018-09-24 2021-12-29 Amgen Inc Systèmes et procédés de dosage interventionnel
CA3110371A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
MA53815A (fr) 2018-10-02 2022-01-05 Amgen Inc Systèmes d'injection pour administration de médicament avec transmission de force interne
TW202408605A (zh) 2018-10-05 2024-03-01 美商安進公司 具有劑量指示器之藥物遞送裝置
BR112021007016A2 (pt) 2018-10-15 2021-07-13 Amgen Inc. dispositivo de administração de fármaco tendo mecanismo de amortecimento
MA53913A (fr) 2018-10-15 2022-01-19 Amgen Inc Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
US11213620B2 (en) 2018-11-01 2022-01-04 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
US20220031939A1 (en) 2018-11-01 2022-02-03 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
JP7510952B2 (ja) 2019-04-24 2024-07-04 アムジエン・インコーポレーテツド シリンジ滅菌確認アセンブリ及び方法
CA3148261A1 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
CN116194585A (zh) 2020-09-22 2023-05-30 美国杰科实验室有限公司 一种糖基化修饰的促红细胞生成素及其应用
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
CN117279929A (zh) 2021-05-10 2023-12-22 凯奥目生物科学株式会社 抗体组合物的纯化方法
KR20240011135A (ko) 2021-05-21 2024-01-25 암젠 인크 약물 용기를 위한 충전 레시피를 최적화하는 방법
WO2023209074A1 (en) 2022-04-28 2023-11-02 Institut National de la Santé et de la Recherche Médicale Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing
WO2024094457A1 (en) 2022-11-02 2024-05-10 F. Hoffmann-La Roche Ag Method for producing glycoprotein compositions
CN116492448A (zh) * 2023-04-12 2023-07-28 深圳赛保尔生物药业有限公司 负载peg-epo及间充质干细胞的组合物、药物及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5641663A (en) * 1985-11-06 1997-06-24 Cangene Corporation Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
ZA946122B (en) * 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
EP0741187A2 (en) * 1995-05-05 1996-11-06 F. Hoffmann-La Roche Ag Recombinant obese (Ob) proteins
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
ES2208798T3 (es) * 1997-09-01 2004-06-16 Aventis Pharma Deutschland Gmbh Eritropoyetina humana recombinante con un perfil de glicosilacion ventajoso.
AU2346900A (en) 1998-11-30 2000-06-19 Eli Lilly And Company Erythropoietic compounds
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
WO2001068141A2 (en) 2000-03-17 2001-09-20 Maxygen Aps Dispersions of polypeptide conjugates
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
DE60109625T3 (de) * 2000-05-15 2017-08-03 F. Hoffmann-La Roche Ag Flüssige arzneizubereitung enthaltend ein erythropoietin derivat

Also Published As

Publication number Publication date
IS5554A (is) 2001-01-02
PE20010297A1 (es) 2001-03-07
SK286301B6 (en) 2008-07-07
JP2004155787A (ja) 2004-06-03
GT200000109A (es) 2001-12-21
CN1184233C (zh) 2005-01-12
CN1515590A (zh) 2004-07-28
JP2001064300A (ja) 2001-03-13
US6583272B1 (en) 2003-06-24
BG104570A (en) 2001-09-28
US20030120045A1 (en) 2003-06-26
BG65449B1 (bg) 2008-08-29
AR024625A1 (es) 2002-10-16
KR100593143B1 (ko) 2006-06-26
CA2310536A1 (en) 2001-01-02
IT1318606B1 (it) 2003-08-27
PT1064951E (pt) 2007-09-10
GEP20022804B (en) 2002-09-25
GB0016205D0 (en) 2000-08-23
DE122007000064I2 (de) 2010-03-25
EA200000607A1 (ru) 2001-02-26
FR2795734B1 (fr) 2005-09-30
BRPI0002276B1 (pt) 2019-05-14
ES2289985T3 (es) 2008-02-16
GB2353281A (en) 2001-02-21
LU91363I2 (fr) 2007-11-12
NZ505454A (en) 2001-12-21
CA2310536C (en) 2007-09-11
CO5190661A1 (es) 2002-08-29
IL137056A0 (en) 2001-06-14
EP1064951A3 (en) 2002-03-20
TNSN00147A1 (fr) 2005-11-10
OA11442A (fr) 2004-04-28
CN1283664C (zh) 2006-11-08
FR2795734A1 (fr) 2001-01-05
DE60036053D1 (de) 2007-10-04
TWI235667B (en) 2005-07-11
GB2393960B (en) 2004-08-04
AR055650A2 (es) 2007-08-29
NO327043B1 (no) 2009-04-06
ID26447A (id) 2001-01-04
AU736067B2 (en) 2001-07-26
NL300289I1 (nl) 2007-11-01
HUP0002553A3 (en) 2005-11-28
ES2191511B1 (es) 2005-01-01
ATE370748T1 (de) 2007-09-15
MA26746A1 (fr) 2004-12-20
EP1839676A2 (en) 2007-10-03
NO20003372L (no) 2001-01-03
NO2009010I2 (no) 2014-06-02
DE10031839A1 (de) 2001-02-01
RS49928B (sr) 2008-09-29
MXPA00006547A (es) 2004-10-28
SV2002000120A (es) 2002-01-31
CY2007021I2 (el) 2009-11-04
CZ299516B6 (cs) 2008-08-20
GC0000197A (en) 2006-03-29
DK1064951T3 (da) 2007-10-08
KR20010049676A (ko) 2001-06-15
EP1064951A2 (en) 2001-01-03
HU226233B1 (en) 2008-07-28
CY1107719T1 (el) 2010-07-28
HK1068354A1 (en) 2005-04-29
NO2009010I1 (no) 2009-05-25
YU40700A (sh) 2003-12-31
DOP2000000030A (es) 2002-07-15
ES2191511A1 (es) 2003-09-01
AU4274400A (en) 2001-01-04
GB2353281B (en) 2004-06-09
SG92717A1 (en) 2002-11-19
GB2393960A (en) 2004-04-14
EP1839676A3 (en) 2008-09-03
GB2393960C (en) 2012-08-29
SI1064951T1 (sl) 2007-12-31
BRPI0002276B8 (pt) 2021-05-25
HU0002553D0 (en) 2000-08-28
HUP0002553A2 (en) 2001-03-28
CZ20002386A3 (cs) 2002-04-17
ITMI20001479A0 (it) 2000-06-30
NL300289I2 (nl) 2010-02-01
DE60036053T2 (de) 2008-01-03
PA8497801A1 (es) 2001-12-14
HRP20000436A2 (en) 2001-06-30
HK1033328A1 (en) 2001-08-24
EA003777B1 (ru) 2003-08-28
CN1280137A (zh) 2001-01-17
HRP20000436B1 (en) 2008-01-31
NO20003372D0 (no) 2000-06-28
BR0002276A (pt) 2001-12-11
FR07C0051I2 (fr) 2008-05-09
NL300289I9 (nl) 2019-08-21
EP1064951B1 (en) 2007-08-22
TR200001956A2 (tr) 2001-01-22
GB0400086D0 (en) 2004-02-04
PL341187A1 (en) 2001-01-15
CY2007021I1 (el) 2009-11-04
FR07C0051I1 (is) 2007-12-14
LU91363I9 (is) 2018-12-31
DE122007000064I1 (de) 2008-01-03
PL202758B1 (pl) 2009-07-31
UY26228A1 (es) 2000-10-31
ITMI20001479A1 (it) 2001-12-30
SK9872000A3 (en) 2002-06-04
JP3727009B2 (ja) 2005-12-14
MY128500A (en) 2007-02-28

Similar Documents

Publication Publication Date Title
DK1064951T3 (da) Erythropoietinderivater
NO20000885D0 (no) 4-Fenyl-pyridin-derivater
NO20021077D0 (no) Amino-triazolopyridin-derivater
DE60009747D1 (de) Admantan-derivate
DE50010060D1 (de) Thiazolylamid-derivate
EE200100613A (et) 13-metüülerütromütsiini derivaadid
DK1187814T3 (da) 5-phenyl-pyrimidinderivater
ATE338021T1 (de) Substituierte 2-dialkylaminoalkylbiphenyl- derivate
NO20021803D0 (no) Isoksazolkarboksamid-derivater
ATE257148T1 (de) Propargyletherderivate
ATE273272T1 (de) Mevinolinderivate
ATE374747T1 (de) Monofluoralkylderivate
ATE254598T1 (de) 4-hydroxybiphenylhydrazid-derivate
DK1187815T3 (da) 4-phenyl-pyrimidinderivater
ATE293592T1 (de) Resorcinderivate
DK1189886T3 (da) Ethansulfonyl-piperidinderivater
NO20022867D0 (no) Syklopentenon-derivater
NO20020212D0 (no) 3-amino-2-benzyl-1-fenyl-propanderivater
DE60001736D1 (de) 1-trifluorotmethyl-4-hydroxy-7-piperidinyl-aminomethylchroman-derivate
ATE269328T1 (de) 1-cycloalkylpyrazolyl-benzoyl-derivate